The development of EGFR inhibitors gefitinib and erlotinib initially showed dramatic effects in the treatment of lung adenocarcinoma; however, tumours frequently acquire resistance to the drugs, resulting in treatment failure (Sharma et al, 2007; Linardou et al, 2009). Here, EGFR is linked to lung adenocarcinoma.